

**Prequalification of Medicines Programme
WHO PUBLIC INSPECTION REPORT
(WHOPIR)
Finished Product Manufacturer**

Part 1: General information

Name of Manufacturer	Hetero Drugs Limited
Unit number	Unit-III (Formulations)
Production Block	Blocks A and B
Physical address	Survey No.: 51 # 22-110, Jeedimetla, Hyderabad, Zip - 500 055, Andhra Pradesh, India
Date of inspection	3 and 4 August 2009
Type of inspection	Special
Dosage forms(s) included in the inspection	Oral Solid Dosage Forms
Summary of the activities performed by the manufacturer	Production and control

Part 2: Summary
General information about the company and site

Hetero Drugs Limited was established in 1993 and has a corporate office, a research foundation, 3 formulation facilities and 3 bulk drug (API) facilities in and around Hyderabad. See previous reports and SMF for details.

History of WHO and/or regulatory agency inspections

This was the seventh inspection of the site by WHO. A routine type GMP inspection was also planned for August 2009 following this special inspection.

Focus of the inspection

The inspection focused on the production and control of antiretroviral products. The inspection covered data verification including product quality review, data submitted in product dossiers, source data, batch manufacturing records, validation data, stability data, OOS investigations, complaints, deviations and change control. Electronic data were also inspected. The use of the correct APIs as approved, was verified.

This inspection report is the property of the WHO
Contact: prequalinspection@who.int

Inspected Areas

This was a special inspection, where some systems were being inspected focusing mainly on material management, quality control and documentation.

After arrival, the inspectors introduced themselves and exchanged business cards with company representatives. The inspection team briefly explained the functioning of the prequalification program including assessments, inspections, publication of WHOPIRs and the NOC procedure.

Inspectors enquired about the differences in specifications, codes, and batch documents for different markets including WHO, PEPFAR, and India. It was established that the company did not have a computer system to manage materials.

The inspectors requested several documents to start the documentation review:

- the annual products quality review reports
- API specifications
- Approved suppliers list
- Batch records
- Validation protocols and reports and source data
- Complaints register
- Deviations register
- Change control register
- Code change management SOP and record

It was noted that APIs had undergone several changes in codes over the years. For some, two specifications were considered "current" even as these had differences in parameters for impurities.

Various batches of product were inspected and it was verified that the correct APIs were used.

Process validation protocols and reports were inspected. This included verification of source/raw data for selected key steps and data in the corresponding batch records.

Various documents including the APQR, batch records, validation protocols and reports were inspected. No complaints, reworks or returns were reported in 2008.

On the second day, the SOP for stability testing was inspected as well as stability protocols/schedules/programmes for selected products. The source data for stability testing results were verified and compared against the tabulated and submitted data.

Thereafter, quality control testing of received APIs was inspected. This included batches and consignments of materials received and used in products, source data including identification tests, related compounds and assay, preparation of working standards and finished product testing.



Stability testing at different intervals and conditions was verified.

Other documents reviewed:

- Approved vendors list Block A
- Approved vendors list Block B
- SOP "Stability management"
- SOP "Sample testing and release of raw materials"
- SOP "Electronic data (software)/projects backup/retrieval"

Part 3: Conclusion

Based on the areas inspected, the people met and the documents reviewed, and considering the findings of the inspection, including the observations listed in the Inspection Report, Hetero Drugs Ltd, India was considered to be operating at an acceptable level of compliance with WHO GMP guidelines.

All the non-compliances observed during the inspection that were listed in the full report as well as those reflected in the WHOPIR, were addressed by the manufacturer, to a satisfactory level, prior to the publication of the WHOPIR

This WHOPIR will remain valid for 3 years, provided that the outcome of any inspection conducted during this period is positive.